WO2007041502A3 - Methods for determining responsiveness to cancer therapy - Google Patents

Methods for determining responsiveness to cancer therapy Download PDF

Info

Publication number
WO2007041502A3
WO2007041502A3 PCT/US2006/038451 US2006038451W WO2007041502A3 WO 2007041502 A3 WO2007041502 A3 WO 2007041502A3 US 2006038451 W US2006038451 W US 2006038451W WO 2007041502 A3 WO2007041502 A3 WO 2007041502A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer therapy
determining responsiveness
molecular tags
binding
Prior art date
Application number
PCT/US2006/038451
Other languages
French (fr)
Other versions
WO2007041502A2 (en
Inventor
Chris Petropoulos
Mike Bates
Colombe Chappey
Sharat Singh
Ali Mukherjee
Mengxiang Tang
Original Assignee
Monogram Biosciences
Chris Petropoulos
Mike Bates
Colombe Chappey
Sharat Singh
Ali Mukherjee
Mengxiang Tang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monogram Biosciences, Chris Petropoulos, Mike Bates, Colombe Chappey, Sharat Singh, Ali Mukherjee, Mengxiang Tang filed Critical Monogram Biosciences
Publication of WO2007041502A2 publication Critical patent/WO2007041502A2/en
Publication of WO2007041502A3 publication Critical patent/WO2007041502A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Abstract

In certain aspects, the present invention provides methods and compositions for determining whether a cancer cells is likely to respond to treatment with a Her2-acting agent. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.
PCT/US2006/038451 2005-09-30 2006-09-29 Methods for determining responsiveness to cancer therapy WO2007041502A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72270905P 2005-09-30 2005-09-30
US60/722,709 2005-09-30

Publications (2)

Publication Number Publication Date
WO2007041502A2 WO2007041502A2 (en) 2007-04-12
WO2007041502A3 true WO2007041502A3 (en) 2007-10-25

Family

ID=37906799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/038451 WO2007041502A2 (en) 2005-09-30 2006-09-29 Methods for determining responsiveness to cancer therapy

Country Status (1)

Country Link
WO (1) WO2007041502A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9110066B2 (en) 2009-01-15 2015-08-18 Laboratory Corporation Of America Holdings HER-3 antibodies and methods of use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2716301T3 (en) 2007-02-16 2017-10-31 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
CA2729796C (en) * 2008-07-08 2017-07-04 George Mason Intellectual Properties, Inc. Phosphorylated c-erbb2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer
EA022884B1 (en) 2008-08-15 2016-03-31 Мерримак Фармасьютикалз, Инк. METHOD FOR TREATING NEOPLASTIC TUMOR USING ANTI-ErbB3 ANTIBODY
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
DK2544680T3 (en) 2010-03-11 2015-04-27 Merrimack Pharmaceuticals Inc USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130238A1 (en) * 2003-04-01 2005-06-16 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130238A1 (en) * 2003-04-01 2005-06-16 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOVEY ET AL.: "Can Molecular Markers Predict When to Implement Treatment with Aromatase Inhibitors in Invasive Breast Cancer?", CLIN. CANCER RES., vol. 11, no. 13, July 2005 (2005-07-01), pages 4835 - 4842 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9110066B2 (en) 2009-01-15 2015-08-18 Laboratory Corporation Of America Holdings HER-3 antibodies and methods of use

Also Published As

Publication number Publication date
WO2007041502A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
WO2007041502A3 (en) Methods for determining responsiveness to cancer therapy
EA200702278A1 (en) ANTIBODIES SPECIFIC FOR TGF-BETA 1
WO2009005809A3 (en) Compositions and methods for treating and diagnosing cancer
WO2005076743A3 (en) Disaccharide molecules and derivatives thereof and methods of using same
WO2007079164A3 (en) Protein kinase inhibitors
WO2006020060A3 (en) Iap binding compounds
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2008133722A3 (en) Anti human sclerostin antibodies
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
GB0525041D0 (en) Methods, assays and compositions for treating retinol-related diseases
EP3311818A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2009006389A8 (en) Pyrimidine derivatives useful as raf kinase inhibitors
WO2007086904A3 (en) Compositions for use in identification of adenoviruses
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
EA201001223A1 (en) STABILIZED PROTEIN COMPOSITIONS
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2004034988A3 (en) Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody
WO2008061108A3 (en) Phthalazine derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06816031

Country of ref document: EP

Kind code of ref document: A2